315 related articles for article (PubMed ID: 28367616)
21. Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients.
Kushner BH; Kramer K; LaQuaglia MP; Modak S; Cheung NK
Pediatr Blood Cancer; 2006 Mar; 46(3):278-84. PubMed ID: 16124002
[TBL] [Abstract][Full Text] [Related]
22. A comparison of current neuroblastoma chemotherapeutics.
Castel V; Cañete A
Expert Opin Pharmacother; 2004 Jan; 5(1):71-80. PubMed ID: 14680437
[TBL] [Abstract][Full Text] [Related]
23. Neuroblastoma in Turkish children: experience of a single center.
Aydn GB; Kutluk MT; Yalçn B; Büyükpamukçu M; Kale G; Varan A; Akyüz C; Senocak ME; Büyükpamukçu N
J Pediatr Hematol Oncol; 2009 Jul; 31(7):471-80. PubMed ID: 19564739
[TBL] [Abstract][Full Text] [Related]
24. The importance of local control management in high-risk neuroblastoma in South Africa.
van Heerden J; Kruger M; Esterhuizen T; Hendricks M; Geel J; Büchner A; Naidu G; du Plessis J; Vanemmenes B; Uys R; Hadley GP;
Pediatr Surg Int; 2020 Apr; 36(4):457-469. PubMed ID: 32112128
[TBL] [Abstract][Full Text] [Related]
25. [Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use].
Pérel Y; Valteau-Couanet D; Michon J; Lavrand F; Coze C; Bergeron C; Notz A; Plantaz D; Chastagner P; Bernard F; Thomas C; Rubie H
Arch Pediatr; 2004 Jul; 11(7):834-42. PubMed ID: 15234382
[TBL] [Abstract][Full Text] [Related]
26. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
[TBL] [Abstract][Full Text] [Related]
27. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification.
De Bernardi B; Gerrard M; Boni L; Rubie H; Cañete A; Di Cataldo A; Castel V; Forjaz de Lacerda A; Ladenstein R; Ruud E; Brichard B; Couturier J; Ellershaw C; Munzer C; Bruzzi P; Michon J; Pearson AD
J Clin Oncol; 2009 Mar; 27(7):1034-40. PubMed ID: 19171711
[TBL] [Abstract][Full Text] [Related]
28. An analysis of neuroblastoma at a single institution.
Thomas PR; Lee JY; Fineberg BB; Razek AA; Perez CA; Land VJ; Vietti TJ
Cancer; 1984 May; 53(10):2079-82. PubMed ID: 6704895
[TBL] [Abstract][Full Text] [Related]
29. [Occurrence and prognostic impact of selected factors in neuroblastoma in children].
Wieczorek A; Balwierz W
Przegl Lek; 2010; 67(6):393-8. PubMed ID: 21344768
[TBL] [Abstract][Full Text] [Related]
30. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.
Ladenstein R; Philip T; Lasset C; Hartmann O; Garaventa A; Pinkerton R; Michon J; Pritchard J; Klingebiel T; Kremens B; Pearson A; Coze C; Paolucci P; Frappaz D; Gadner H; Chauvin F
J Clin Oncol; 1998 Mar; 16(3):953-65. PubMed ID: 9508178
[TBL] [Abstract][Full Text] [Related]
31. Neuroblastoma: outcome over a 14 year period from a tertiary care referral centre in India.
Agarwala S; Mandelia A; Bakhshi S; Srinivas M; Bajpai M; Gupta AK; Gupta DK; Bhatnagar V
J Pediatr Surg; 2014 Aug; 49(8):1280-5. PubMed ID: 25092090
[TBL] [Abstract][Full Text] [Related]
32. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
33. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
34. Survival after relapse in children with solid tumors: a follow-up study from the Italian off-therapy registry.
Ceschel S; Casotto V; Valsecchi MG; Tamaro P; Jankovic M; Hanau G; Fossati F; Pillon M; Rondelli R; Sandri A; Silvestri D; Haupt R; Cuttini M
Pediatr Blood Cancer; 2006 Oct; 47(5):560-6. PubMed ID: 16395684
[TBL] [Abstract][Full Text] [Related]
35. [The identification of minimal residual disease in the bone marrow and peripheral blood in neuroblastoma. The prognostic and therapeutic implications].
Faulkner LB; Tamburini A; Tintori V; Paoli A; Tondo A; Bernini G; Medicina D; Brisigotti M; Corrias MV; Scaruffi P; Rosanda C; Lo Piccolo MS; Viscardi E; Milanaccio C; Garaventa A; De Bernardi B
Pediatr Med Chir; 1998; 20(3):175-8. PubMed ID: 9744008
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma.
Hero B; Hunneman DH; Gahr M; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):220-3. PubMed ID: 11464889
[TBL] [Abstract][Full Text] [Related]
37. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma.
Basta NO; Halliday GC; Makin G; Birch J; Feltbower R; Bown N; Elliott M; Moreno L; Barone G; Pearson AD; James PW; Tweddle DA; McNally RJ
Br J Cancer; 2016 Oct; 115(9):1048-1057. PubMed ID: 27701387
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study.
Katzenstein HM; Bowman LC; Brodeur GM; Thorner PS; Joshi VV; Smith EI; Look AT; Rowe ST; Nash MB; Holbrook T; Alvarado C; Rao PV; Castleberry RP; Cohn SL
J Clin Oncol; 1998 Jun; 16(6):2007-17. PubMed ID: 9626197
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcomes in patients with stage IV neuroblastoma.
Escobar MA; Grosfeld JL; Powell RL; West KW; Scherer LR; Fallon RJ; Rescorla FJ
J Pediatr Surg; 2006 Feb; 41(2):377-81. PubMed ID: 16481255
[TBL] [Abstract][Full Text] [Related]
40. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
